Get the Stockscreener App
3.06
3.77%
-0.12
Pre-market:
3.14
0.08
+2.61%
Maxcyte Inc stock is traded at $3.06, with a volume of 628.71K.
It is down -3.77% in the last 24 hours and down -24.82% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$3.18
Open:
$3.17
24h Volume:
628.71K
Relative Volume:
1.10
Market Cap:
$323.48M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-9.00
EPS:
-0.34
Net Cash Flow:
$-25.39M
1W Performance:
-12.82%
1M Performance:
-24.82%
6M Performance:
-24.07%
1Y Performance:
-26.44%
1-Day Range:
$2.98
$3.195
1-Week Range:
$2.76
$3.58
52-Week Range:
$2.76
$5.26
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
3.06 | 323.48M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
Stifel Nicolaus Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price - Defense World
What is William Blair’s Estimate for MaxCyte Q1 Earnings? - Defense World
MaxCyte files annual report with SEC By Investing.com - Investing.com Australia
MaxCyte core business revenue grows despite overall decline By Investing.com - Investing.com Australia
Stifel cuts MaxCyte stock price target to $9 from $11 By Investing.com - Investing.com Canada
Stifel cuts MaxCyte stock price target to $9 from $11 - Investing.com
MaxCyte stock touches 52-week low at $3.11 amid market challenges - Investing.com India
MaxCyte’s Promising Financial Outlook and Strategic Growth Justify Buy Rating - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2024 Earnings Call Transcript - Insider Monkey
MaxCyte price target lowered to $6 from $8 at BTIG - TipRanks
MaxCyte stock price target cut to $6 at BTIG By Investing.com - Investing.com South Africa
MaxCyte price target lowered to $9 from $11 at Stifel - TipRanks
MaxCyte stock price target cut to $6 at BTIG - Investing.com India
MaxCyte files annual report with SEC - Investing.com India
MaxCyte core business revenue grows despite overall decline - Investing.com India
Maxcyte Sees 2025 Core Revenue To Grow 8% To 15% -March 12, 2025 at 03:20 am EDT - Marketscreener.com
MaxCyte reports a return to core revenue growth in FY24 - DirectorsTalk Interviews
MaxCyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MaxCyte’s Strategic Expansion and Financial Resilience Drive Buy Rating - TipRanks
MaxCyte shares tumble as Q4 revenue plunges despite beating estimates By Investing.com - Investing.com Australia
MaxCyte shares tumble as Q4 revenue plunges despite beating estimates - Investing.com India
MaxCyte reports Q4 EPS (10c), consensus (12c) - TipRanks
MAXCYTE, INC. SEC 10-K Report - TradingView
MaxCyte Reports 2024 Financial Results with Core Growth - TipRanks
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance - The Manila Times
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 ... - Bluefield Daily Telegraph
MaxCyte (MXCT) Expected to Announce Quarterly Earnings on Tuesday - Defense World
MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments - MSN
MaxCyte Expands Stock Capital with New Issuance - TipRanks
MaxCyte, Inc.'s (LON:MXCT) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors - Simply Wall St
Institutional owners may take dramatic actions as MaxCyte, Inc.'s (LON:MXCT) recent 11% drop adds to one-year losses - Simply Wall St
MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MSN
Andrew Mancini, PhD's Profile Page - Technology Networks
263,833 Shares in MaxCyte, Inc. (NASDAQ:MXCT) Bought by Rice Hall James & Associates LLC - MarketBeat
TG Therapeutics advancing CAR T-cell therapy toward Phase 1 trial - Multiple Sclerosis News Today
MaxCyte Experiences Shift in Major Holdings by BlackRock - TipRanks
BlackRock Increases Stake in MaxCyte to 7.66% - TipRanks
Bio Buyout: MaxCyte Acquires SeQure - Law Street Media
BlackRock Adjusts Holdings in MaxCyte, Inc. - TipRanks
TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases - MSN
TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform - News-Medical.Net
TG Therapeutics Licenses Maxcyte Tech to Develop Cell Therapies for Autoimmune Disease - Genetic Engineering & Biotechnology News
MaxCyte Signs Licensing Deal With TG Therapeutics For Next-Gen Autoimmune Cell Therapies - Nasdaq
MaxCyte signs SPL deal with TG Therapeutics - ShareCast
MaxCyte Signs Platform License Deal With TG Therapeutics -February 12, 2025 at 05:07 am EST - Marketscreener.com
MaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programs - MSN
MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics -February 12, 2025 at 04:37 am EST - Marketscreener.com
MaxCyte and TG Therapeutics partner on next-gen cell therapy for MS - DirectorsTalk Interviews
MaxCyte Partners with TG Therapeutics for Autoimmune Cell Therapy - TipRanks
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - The Manila Times
Maxcyte Says Enters Strategic Platform License With TG Therapeutics -February 12, 2025 at 02:18 am EST - Marketscreener.com
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maxcyte Inc Stock (MXCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Johnston John Joseph | Director |
Jan 27 '25 |
Sale |
4.64 |
3,000 |
13,935 |
141,950 |
| Sandoval David I. | GENERAL COUNSEL |
Jan 13 '25 |
Sale |
4.54 |
4,466 |
20,272 |
41,447 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Sale |
4.01 |
3,000 |
12,021 |
141,950 |
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):